20 reports

Also, this disorder has a strong association with asthma.

  • Allergy Drug
  • Ear Disease
  • World
  • Novartis AG
  • Sanofi S.A.
  • Products under Development by Companies, H2 2017
  • Number of Products under Development by Indication, H2 2017

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2017 Summary Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled...

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative
  • Sensorion S.A.
  • Products under Development by Companies, H1 2018
  • Number of Products under Development by Indication, H1 2018

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Molecular Diagnostic
  • Therapy
  • Sensorion S.A.

NO has a solid place in asthma management.

  • Drug Test
  • United States
  • Alere Inc.
  • Dräger Group
  • Thermo Fisher Scientific, Inc.
  • UR-63325 - Drug Profile

In animal asthma models, the molecule shows very good efficacy in both inflammatory and respiratory parameters.

  • Ear Disease
  • Molecular Diagnostic
  • Turkey
  • World
  • Product Initiative

UR-## IS A H## RECEPTOR ANTAGONIST WHICH IS BEING EVALUATED FOR RESPIRATORY CONDITIONS SUCH AS ASTHMA.

  • Ear Disease
  • United States
  • AudioCure Pharma GmbH
  • Autifony Therapeutics Limited
  • Cochlear Limited

Presented post approval study results at the American Thoracic Society International Conference that demonstrated the Alair™ Bronchial Thermoplasty System reduced complications, including severe asthma exacerbations and asthma-related hospitalizations, in adult patients with severe

  • Clinical Trial
  • Ear Disease
  • Pathology
  • Therapy
  • GlobalData's company
  • TINNITUS - PIPELINE BY AUDIOCURE PHARMA GMBH, H1 2018
  • TINNITUS - PIPELINE BY AURIS MEDICAL HOLDING AG, H1 2018

The company' s lead product candidate, dexpramipexole, is an orally bioavailable small molecule which is used for the treatment of asthma, other eosinophilassociated disorders, and for amyotrophic lateral sclerosis (ALS).

  • Ear Disease
  • United States
  • World
  • Product Initiative
  • Auris Medical Holding AG
  • Meniere Disease - Pipeline by Orbis Biosciences Inc, H1 2018

Following an initial one month lead-in period, eligible subjects were randomized ##:## to a single intratympanic injection of OTIVIDEX or placebo.

  • Ear Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.
  • FEATURED NEWS & PRESS RELEASES

IN ELDERLY PATIENTS AND THOSE WITH COPD OR ASTHMA, COMPARED TO MOXIFLOXACIN, THE NUMBER OF RESPONDERS ON SOLITHROMYCIN WAS NUMERICALLY GREATER. ##-Aug-2015 Cempra, Inc. announced that the U. S.

  • Anti-Infective
  • Ear Disease
  • United States
  • Product Initiative
  • Cempra, Inc.
  • Sep 15, 2016: Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO in Patients with History of Otitis Media Requiring Tympanostomy Tubes

In elderly patients and those with COPD or asthma, compared to moxifloxacin, the number of responders on solithromycin was numerically greater. ##-Aug-2015 Cempra, Inc. announced that the U. S.

  • Anti-Infective
  • Ear Disease
  • Therapy
  • United States
  • Product Initiative
  • TINNITUS - PIPELINE BY AUDIOCURE PHARMA GMBH, H2 2017
  • AUDIOCURE PHARMA GMBH

The company' s lead product candidate, dexpramipexole, is an orally bioavailable small molecule which is used for the treatment of asthma, other eosinophilassociated disorders, and for amyotrophic lateral sclerosis (ALS).

  • Ear Disease
  • Therapy
  • United States
  • Product Initiative
  • Auris Medical Holding AG
  • ACUTE SENSORINEURAL HEARING LOSS - PIPELINE BY ORBIS BIOSCIENCES INC, H2 2016
  • NORDMARK ARZNEIMITTEL GMBH & CO. KG

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear Disease
  • United States
  • World
  • Product Initiative
  • Auris Medical Holding AG

More than one third of all adults suffer from one form or another of vestibular disorders.

  • Ear Disease
  • Pharmaceutical
  • France
  • Deals & Alliance
  • Sensorion S.A.
  • Clinical Trial profile. 15 Trial Title
  • Latest Clinical Trials News on Otitis Media

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Ear Disease
  • World
  • Product Initiative
  • Pipeline by Xigen SA, H2 2017

Patients were randomized to receive AM-## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Ear Disease
  • Psychotic Disorder
  • Turkey
  • World
  • Product Initiative

The poster presentation, reported on the cardiac effects of nVNS in asthma patients using nVNS to treat acute bronchospasm.

  • Cardiovascular Disease
  • Clinical Trial
  • Ear Disease
  • Therapy
  • GlobalData's company
  • Meniere Disease - Companies Involved in Therapeutics Development
  • Meniere Disease - Pipeline by Orbis Biosciences Inc, H2 2017

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Therapy
  • United States
  • Product Initiative
  • PIPELINE BY KNOPP BIOSCIENCES LLC, H2 2016

The molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are ##, ##, ## and ## respectively.

  • Ear Disease
  • Neurological Disorder
  • Therapy
  • United States
  • Company Operations